COILED THERAPEUTICS

Unravelling Cancer's Blueprint

Precision oncology advancing first-in-class therapeutics for patients with high-risk cancers.

AIM: **COIL** | OTCQB: **COTXF**

INVESTOR PRESENTATION Q3 2026

Disclaimer

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

For the purposes of this document, the "Presentation" shall mean and include this document, the slides that follow, the oral briefing provided by the Company in connection with the information herein, the question and answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with the Presentation or otherwise made available in connection with the Company. This Presentation has been prepared by Coiled Therapeutics plc (the "Company"). This Presentation has been prepared for information only and solely for use by the Company at presentations to a limited number of parties. This Presentation is not an approved prospectus or other equivalent offering document under the securities laws of any jurisdiction.

Neither this Presentation nor any copy of it may be (a) taken or transmitted into Canada, Japan, the Republic of South Africa or any other jurisdiction (or their territories or possessions) in which it would be unlawful to do so (except Australia, subject to compliance with applicable Australian securities laws, and the United States of America, subject to applicable United States of America securities laws); or (b) distributed to any individual outside Canada, Japan or the Republic of South Africa who is a resident thereof or who is a resident of any other jurisdiction in which it would be unlawful to take or transmit this Presentation in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this Presentation in or to persons subject to other jurisdictions (including Australia and the United States of America) may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. By accepting delivery of this Presentation and by reading the information contained herein (including this notice), the recipient unconditionally agrees to be bound by the following limitations and obligations contained in this notice. Neither this Presentation, its contents, nor any part thereof have been approved (for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA")) or verified by an authorised person within the meaning of FSMA. Reliance on this Presentation for the purposes of engaging in any investment activity may expose an individual to a significant risk of losing all the assets invested. The information contained in this Presentation is being supplied to a very limited number of persons for information purposes only. This Presentation is not an offer to sell or invitation or solicitation of any offer to acquire securities of the Company, nor does it form a prospectus or part of any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) nor does it constitute an offer to the public in the United Kingdom (within the meaning of Regulation 7 of Public Offers and Admissions to Trading Regulations 2024/105 ("POATRs") and no offer will be made unless the offer is of a kind specified in Part 1 of Schedule 1 to the POATRs or a combination of two or more such kinds of offers, pursuant to Regulation 12 of the POATRs.. It shall not form the basis of, or be relied on in connection with, or act as invitation or inducement to enter into, any contract or commitment whatsoever. No offer of securities is being or will be made in circumstances which would require a prospectus or similar document to be approved. The Presentation is strictly confidential, is being supplied to you solely for your information and may not be distributed or re-distributed (including to the press) or passed to any other person, may not be copied in any form and may not be published, in whole or in part, for any purpose. Failure to comply with this restriction may, inter alia, constitute a violation of applicable securities laws. Certain information contained in the Presentation may be non-public, proprietary and highly confidential. Accordingly, by accepting and using this document, you will be deemed to agree not to disclose any information contained in the Presentation except as may be required by law. The Presentation may contain unpublished price sensitive information with regard to the Company and/or its securities. Recipients of the Presentation should not deal or encourage any other any other person to deal in the securities of the Company whilst they remain in possession of such unpublished price sensitive information and until the transaction described in the Presentation is announced. Dealing in securities of the Company when in possession of unpublished price sensitive information could result in liability under the insider dealing restrictions set out in the Criminal Justice Act 1993 and the Market Abuse Regulations (EU) No 596/2014 (incorporated into UK law by virtue of the European Union (Withdrawal) Act 2018). This Presentation may contain information which is not generally available, but which, if available, would or would be likely to be regarded as relevant when deciding the terms on which transactions in the shares of the Company should be effected. Unreasonable behaviour based on such information could result in liability under the market abuse provisions of FSMA. This Presentation is directed at, and is only being made available to, persons in the United Kingdom who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (Regulation 2017/1129) as applicable in the United Kingdom and as amended by the Prospectus (Amendment etc) (EU Exit) Regulations 2019 (SI2019/1234) and who are (a) persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), being investment professionals or (b) persons to whom Article 49(2) of the Order applies, being high net worth companies, unincorporated associations, partnerships or trusts or their respective directors, officers or employees as described in Article 49 of the Order. Persons who do not fall within one of the categories of persons described above should not rely on this Presentation nor take any action upon it and should return it to the Company immediately. By accepting or electronically accessing this Presentation, the recipient represents, warrants and undertakes to the Company that they (a) are a person who falls within the above description of persons entitled to receive the Presentation, (b) will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (c) have read and agree to comply with the contents of this notice. The recipient further agrees to return to the Company, upon request, all documents and other material held by it relating to the project referred to in the Presentation. Persons falling within one of the categories of persons described above must comply with the terms of this disclaimer and they will conduct their own analyses or other verification of the data set out in this presentation and bear the responsibility for all or any costs incurred in doing so. Certain of the information contained in this Presentation has been obtained from published sources prepared by other parties. Certain other information has been extracted from unpublished sources prepared by other parties which have been made available to the Company. The information contained in the Presentation, which does not purport to be comprehensive, has been provided by the Company's management and has not been verified as to its accuracy, completeness or otherwise by the Company, by any of the Company's advisers or by any of their respective shareholders, directors, advisers, agents or affiliates. It may be subject to updating, completion, revision and/or amendment and such information may change materially at any time without further notice. SP Angel Corporate Finance LLP ("SP Angel"), CPS Capital Group Pty Ltd ("CPS Capital") and Shard Capital Partners LLP ("Shard Capital") are the appointed brokers to the Company and are acting in the provision of corporate finance business to the Company, within the meaning of the Financial Conduct Authority's Conduct of Business Sourcebook ("COBS"), and no-one else in connection with the matters contained in this Presentation. Accordingly, recipients should note that SP Angel, CPS Capital and Shard Capital are neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of it under the COBS nor for providing advice in relation to the matters contained in this Presentation. SP Angel, which is a member of the London Stock Exchange, is authorised and regulated in the United Kingdom by the Financial Conduct Authority (the "FCA") is acting as nominated adviser and joint broker to the Company in connection with Admission. For the avoidance of doubt, neither SP Angel, CPS Capital nor Shard Capital have authorised or approved the contents of the Presentation. The Company, SP Angel, CPS Capital and Shard Capital and their respective shareholders, directors, officers, agents, employees or advisers or any other person do not give, have not given, will not give and do not have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability, fairness, sufficiency or completeness of the information or opinions in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability is expressly disclaimed. Accordingly, the Company, SP Angel, CPS Capital and Shard Capital and their respective shareholders, directors, officers, agents, employees or advisers or any other person do not take any responsibility for, nor will they accept any liability whether direct or indirect, express or implied, contractual, tortuous, statutory or otherwise, save in the case of fraud, in respect of the accuracy, reliability, fairness, sufficiency or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements, negligent or otherwise, or for any direct, indirect or consequential loss or damage suffered by any person, howsoever arising, from the use of this Presentation. Each recipient must conduct its own independent investigation and analysis of the Company and of the information contained in this Presentation and obtain separate and independent verification of information and opinions contained in this Presentation as part of their own due diligence, and bear all the costs of doing so. This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. Forward-looking statements are identified by, amongst other things, the use of such terms as "anticipate", "assumes", "believe", "could", "envisage", "estimate", "expect", "forecast", "potential", "intend", "may", "plan", "should", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are statements, which are intended as a guide only, regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other important factors that relate to events and depend on circumstances that may or may not occur in the future and/or which are beyond the control of the Company (including, but not limited to, future market conditions, legislative and regulatory changes, the actions of governmental regulators, changes in the political, social, regulatory and/or economic framework in which the Company operates). These forward-looking statements are not guarantees of future performance of the Company and reflect assumptions and subjective judgements by the Company that are difficult to predict, qualify and/or quantify. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation. No representation or warranty is given as to the achievement or reasonableness of any projections, estimates, prospects or returns or any other forward-looking statements. No representation or warranty is made or assurance given that the statements, projections and forecasts contained in this Presentation will be borne out in practice or that the Company will perform as projected and the Company does not assume responsibility for verifying any of such statements, projections or forecasts. Neither the Company nor any persons shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on any statement in or omission from this Presentation. The Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or any additional information or to correct any inaccuracies in it, or omissions from it, which may become apparent. This Presentation is being delivered to interested parties for information only and upon the express understanding that such recipients will use it only for the purpose set out above. Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. The Company reserves the right without any notice or liability to the recipient of this Presentation or its advisers to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; (iii) agree variations to the property, rights and liabilities comprised in the Company; and (iv) negotiate at the same time with more than one person. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. This Presentation should not be considered a recommendation by the Company or any of its affiliates in relation to any prospective acquisition of shares in the Company. If you are in any doubt about the investment to which this Presentation relates, you should consult a person authorised by the FCA who specialises in advising on securities of the kind described in this Presentation.

Why Coiled?

1 Unlocking a Validated Cancer Dependency with No Approved Targeted Therapy

AO-252 is the only clinical-stage programme targeting TACC3, a biologically validated cancer dependency implicated across multiple aggressive solid tumours with independent DepMap analysis supporting TACC3 as a selective tumour vulnerability.

2 Human Proof-of-Concept Already Emerging

An 80% Clinical Benefit Rate has been observed before dose optimisation. No serious adverse events have been reported, and maximum tolerated dose has not yet been reached, leaving meaningful upside as exposure increases.

3 Designed to Win Where Others Cannot

AO-252 combines oral administration, blood-brain barrier penetration, a multi-modal mechanism of action, and biomarker-driven patient selection to support both monotherapy and combination therapy in a single small molecule.

4 Catalyst-Rich Through 2027

Multiple upcoming clinical and strategic milestones expected, include expansion cohort data, biomarker validation, combination studies, partner-relevant H2 2026 data sets, regulatory interactions.

5 Multiple Paths to Shareholder Value

Clinical development is focused on commercially attractive indications and partner-relevant data generation, preserving multiple pathways to value creation, including independent development, licensing and strategic partnerships.

6 Experienced Oncology Leadership

Management previously repeatedly advanced oncology assets from discovery through clinical development, public markets, and strategic transactions.

Clinical Differentiation



TACC3: A Validated Cancer Dependency With No Approved Targeted Therapy

COILED THERAPEUTICS

Validated Biology

Broad Institute DepMap analysis across thousands of cancer cell lines confirms TACC3 as a selective survival dependency in multiple tumour types. Similar approaches helped validate targets including BRCA, KRAS and MET before successful therapies emerged.

Cancer Dependency

Preclinical research suggests many cancer cells depend on TACC3 for survival, while healthy adult tissue demonstrates significantly lower dependence.

Centrosome Amplification Driver

TACC3 drives centrosome amplification, genomic instability and tumour progression—hallmarks of aggressive cancers.

Now Druggable

Advances in structure-guided drug design have transformed TACC3 from an historically undruggable target into a clinically actionable opportunity.

AO-252: One Molecule. Multi-Modal MOA.

1

Multi-Modal Mechanism of Action

AO-252 disrupts TACC3, causing DNA damage, replication stress in cancer cells and immune activation.

2

Innate Immune Activation (cGAS/STING)

Damaged DNA activates cGAS/STING, triggering an anti-tumour immune response

3

Direct Cancer Killing + Immune Activation

AO-252 attacks tumours through direct cancer-cell killing and immune activation



AO-252 combines targeted cytotoxicity with innate immune activation in a single oral small molecule.

Phase 1 Clinical Trial: Robust Early Signals

Clinical benefit while dose optimisation remains ongoing.

COILED THERAPEUTICS

PHASE 1 (NCT06136884)

80%

Clinical Benefit Rate

Cohort 4b — 2x daily dosing; 20% ORR

NO SAEs

No Serious Adverse Events

Room to optimise as maximum tolerated dose not reached

5

Median Prior Therapies

Heavily pre-treated population

≥6 mo

Duration of Response

vs. 2–3 mo. salvage benchmark

ENCOURAGING CLINICAL SIGNALS

Bid Dosing increased CBR from 40% to 80%

Durability & Tumour Reductions observed in ovarian and endometrial cancer, before targeted exposure levels have been achieved

Maximum Tolerated Dose not yet reached, supporting continued optimisation

July 2026 New formulation introduced with clinical data generation to follow

Clinical Development Strategy

AO-252 is initially focused on indications where differentiated biology, early clinical activity and significant unmet need create the clearest path to value creation.

Ovarian Cancer

Lead Expansion Cohort
Early Efficacy Observed

Why?

Advanced disease following PARP inhibitor resistance with few effective treatment options remaining

Current Treatment

- PARP inhibitors & ADCs

Why AO-252?

- Distinct DNA damage mechanism
- Brain-penetrant
- Early clinical activity observed
- Large unmet need

Prostate Cancer

Second Expansion Cohort
Biomarker-driven development

Why?

Treatment resistance develops after androgen receptor therapies despite multiple approved options

Current Treatment

- AR inhibitors, Taxanes & Radioligands

Why AO-252?

- AR-independent mechanism
- Biomarker strategy
- Combination potential
- Large validated commercial market

Platform Expansion Opportunities

Following clinical validation, potential to expand across:

- Brain metastases
- Additional solid tumours
- IO combinations
- ADC combinations

PURPOSE-BUILT CLINICAL DESIGN

To generate relevant clinical evidence for partners supporting Phase 2 planning, biomarker validation, future indication expansion.

Targeting 20-30 Patients Expansion Cohorts by Q3 2026

Commercial Opportunity

AO-252 is being developed within commercially validated oncology markets where precision medicines have already created multi-billion-dollar value.

350K+

Estimated Addressable Patients

Biomarker-defined populations across ovarian, prostate, TNBC, endometrial, gastric, and lung cancers in the US and Europe.

>$20B

Proven Oncology Markets

PARP, CDK4/6 and AR inhibitors demonstrate the commercial success of precision oncology and biomarker-driven treatment.

>$3B

Recent Strategic Transaction Benchmark

Johnson & Johnson's acquisition of Halda highlights continued pharmaceutical demand for differentiated early-stage precision oncology assets.

Commercial Validation

DNA Repair PARP inhibitors established multi-billion-dollar markets by targeting DNA repair biology.

Precision Medicine CDK4/6 inhibitors demonstrated the value of biomarker-informed treatment selection.

Resistant Disease AR inhibitors created large commercial opportunities by treating patients with therapy-resistant disease.

Value Creation Roadmap

2026–2027 CLINICAL MILESTONES

H2 2026
Clinical Dataset Build-Out

- Initial data from new-generation formulation
- Dose escalation expansion data
- Accelerated patient enrolment
- Expansion cohorts initiated
- Target 20–30 patients treated
- Combination trial initiation

H1 2027

- Key Value Inflection
- Preliminary efficacy dataset
- ~50-patient safety database
- Biomarker validation
- Indication specific cohort updates
- Partnering data package

H2 2027

- Strategic Execution
- Big Pharma partnering discussions
- Registrational pathway alignment
- RP2D confirmation
- Potential Phase 2 strategy

Recent Oncology Transactions

Comparable transactions vary by modality and maturity but demonstrate sustained pharmaceutical demand for differentiated early-stage oncology assets.

DATE	ACQUIRER	TARGET	UPFRONT PAYMENT	MILESTONES / CVRS	TOTAL DEAL VALUE	PATIENT NUMBER	PHASE	INDICATIONS
Jul-26	Novartis	Myricx Bio	$1.1B	Up to $400M	~$1.5B	18	Pre-clinical / ADC payload	Multiple solid tumours
Apr-26	Eli Lilly	Kelonia	$3.25B	$3.75M	$7.0B	4	(Platform play)	Leukemia
Mar-26	Merck	Terns Pharma	-	-	$6.7B	85	Phase 1/2	Chronic Leukemia
Nov-25	J&J	Halda	$3.05B	-	$3.05B	31	Phase 1/2	Prostate and ER Breast
Jan-25	**Eli Lilly**	**Scorpion**	**$1.5B**	**$1.0B**	**$2.5B**	**40-50**	**Phase 1**	**ER+ Breast**
May-24	Genmab	Profound Bio	$2.0B	-	$2.0B	80	Phase 1/2	Ovarian & Endometrium
Jan-24	J&J	Ambrx	$2.0B	-	$2.0B	51	Phase 1	Prostate

Pipeline: Multi-Modal, Multi-Indication



Management & Board of Directors

Dr Sotirios Stergiopoulos

EXECUTIVE CHAIRMAN

- Physician executive with extensive pharmaceutical experience, particularly in Oncology
- Former CMO of multi-billion dollar Euronext-listed Ipsen
- Former Attending Physician and trainee at Albert Einstein College of Medicine, Harvard Medical School, and National Institutes of Health
- Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from Johns Hopkins University; Medical Degree from Poznan University of Medical Sciences (Poland)

Sridhar Vempati

CHIEF EXECUTIVE OFFICER

- ~20 years in drug discovery, oncology research & business strategy; proven track record advancing novel therapeutics from concept to clinical development
- Co-founded A2A Pharmaceuticals in 2016, previous business development roles at Ironwood Pharmaceuticals and Rafael Pharmaceuticals, and Equity Research analyst at Jefferies LLC
- Postdoctoral fellowship in leukaemia research at Dana Farber Cancer Institute (Harvard University), PhD in molecular biology from Ludwig-Maximilians-University, Germany, MBA from Boston University

NON-EXECUTIVE DIRECTORS

Jean Duvall (Independent NED)

- CEO & Director at Repronovo SA
- Former director, Exec VP & Group General Counsel at Ferring International Center

Craig Tooman (Independent NED)

- President, Chief Executive Officer, Board Member and former CFO, Silence Therapeutics
- Former CuraVac, Vyome Therapeutics, Aratana Therapeutics

Stephen West

- Fellow Chartered Accountant, 30+ years' international finance, corporate and public company experience
- Co-founder of EnergyPathways plc (AIM:EPP), Roquefort Therapeutics plc, TollCyto Therapeutics Ltd & ParisBio Ltd

Dr Andrew Dean

- Head of Oncology, St John of God Subiaco Hospital, Western Australia; consults for GenesisCare
- Board member, Valo Therapeutics; research expertise in solid tumour molecular profiling and novel ovarian cancer therapies

Five Reasons

1 First-in-Class Clinical Asset

- ✓ Human Proof-of-Concept Emerging
- ✓ Only Clinical-Stage TACC3 Programme
- ✓ Clinical Activity Before Optimisation

2 Commercially Relevant Development Strategy

- ✓ Ovarian
- ✓ Prostate
- ✓ Biomarkers

3 Near-Term Value Inflection Points

- ✓ 2026–2027 Catalysts

4 Multiple Paths to Value Creation

- ✓ Independent development
- ✓ Licensing
- ✓ Regional deals
- ✓ Acquisition

5 Experienced Team With Prior Execution

- ✓ Biomea
- ✓ Ipsen
- ✓ Silence
- ✓ Harvard

Coiled Development Strategy



Capital Structure & Financials

AIM Admission	**27 March 2026**
Placing Price	**10 pence per share**
Gross Fundraise	**£8.5 million (~$11.3M USD)**
Market Cap	**~£40 million (May 2026)** *Share price ~10p*
Total Shares Outstanding	**425,856,539**

Fully funded into 2027, securing operations through major H2 2026 clinical data readouts.



Thank You

Coiled Therapeutics plc | www.coiledplc.com | info@coiledplc.com

Harbor Access Investor Relations
Matt Kelly
matt@harbor-access.com
+1 475 477 9403

AIM: **COIL** | OTCQB: **COTXF**

COILED THERAPEUTICS

Appendix

AIM: **COIL** | OTCQB: **COTXF**

Company Strategy & History

2025

Coiled Therapeutics plc spun out of A2A Pharmaceuticals to advance AO-252, a first-in-class TACC3 inhibitor already in Phase 1 clinical development.

2026

March – Reverse takeover of AIM-listed Roquefort Therapeutics, raised £8.5 million at 10 pence per share from institutional and retail investors, and began trading on AIM under the ticker COIL on 27 March 2026.

May – The Company commenced cross-trading on the OTCQB Venture Market (COTXF), extending access to US-based investors.

Prior Execution

The founders previously created Biomea Fusion through the spin-out of A2A's MLL-Menin programme, culminating in a Nasdaq IPO and a market capitalisation exceeding US$1 billion.

Coiled applies the same disciplined development model to a more advanced clinical asset.

Company Facts

Exchange	**AIM (London) + OTCQB (US)**
Tickers	**COIL (AIM) | COTXF (OTCQB)**
AIM Admission	**27 March 2026**
OTCQB Listing	**19 May 2026**
Shares Outstanding	**425,856,539**
Placing Price	**10 pence per share**
Gross Proceeds	**£8.5 million (~$11.3M USD)**
Market Cap	**~£40 million (May 2026)**
ISIN	**GB00BSHRN331**

US IR: Harbor Access +1 475 477 9404

TACC3: A Validated Cancer Dependency

WHAT IS TACC3?

TACC3 is a protein essential for cell division. Many cancers become highly dependent on TACC3 to sustain growth and survive genetic stress.

Why is it important?

Why it matters

- Frequently overexpressed in aggressive cancers
- Linked to tumour progression and poorer outcomes
- Supports chromosome stability and cancer cell division
- Identified as a survival dependency across multiple tumour types

Why is it considered validated?

TACC3 is considered a validated target because cancer cells depend on it for survival, and disrupting its function has been shown to impair tumour growth.

Why it matters

- Decades of research confirm TACC3's critical biological role
- Cancer studies consistently show elevated TACC3 in tumours
- Genetic and pharmacological inhibition reduces tumour growth in preclinical models
- Clinical datasets associate high TACC3 expression with worse patient outcomes

Novel Drug Target. Proven Cancer Biology.

TACC3 has been extensively validated as a cancer dependency but has historically remained difficult to target therapeutically, creating a differentiated development opportunity.

WHY DOES IT MATTER NOW?

Historically considered difficult to target, advances in drug design are now enabling companies such as Coiled to pursue this well-validated cancer vulnerability.

AO-252 Mechanism of Action Visual

MULTI-TARGETED PPI DISRUPTION

By disrupting TACC3's protein-protein interactions, AO-252 induces mitotic & replication stress through impairment of the DNA damage repair process and activation of immunity, leading to cancer cell death, particularly in TP53-mutant cells, while showing minimal toxicity in healthy cells. AO-252 operates through a sophisticated mechanism that inhibits multiple critical protein-protein interactions at the TACC3 C-terminal domain. This disruption cascades across key proteins including DNA-PK, PARP1, BRCA, KU70, KIFC1, MBD2, and HDAC2 - collectively involved in mitosis, DNA damage repair, replication, and transcription.



Biomarker Strategy

Patient selection based on TP53 mutation status, high centrosomal amplification, and elevated TACC3 expression ensures precision targeting of responsive populations.

Robust Pre-Clinical Validation

AO-252 demonstrated **tumour regression as monotherapy** across multiple difficult-to-treat solid tumour models, including ovarian, triple-negative breast cancer (TNBC), endometrial, gastric, and prostate cancers. Notably, the compound showed robust efficacy in in vivo brain metastases models, addressing a critical unmet medical need.

Tumour growth inhibition (TGI) of 88-120% were observed, with partial to complete responses consistently achieved across all tested indications. Additional strong activity was confirmed in NSCLC, SCLC, bladder, and esophageal cancer models.

MDA-MB-231 (TNBC)



HEC-59 (Endometrium)



SKOV3 (Ovarian)



VCAP (Prostate)



Clean Safety Profile

- No toxicities observed in 28-day GLP studies (rats & dogs)
- Negative genetic toxicology across AMES and clastogenicity assays

Selective Kinase Inhibition

- Only 4 of 468 kinases inhibited >65% at 1µM concentration
- Demonstrates exceptional target selectivity

Strong Therapeutic Index

- Therapeutic window of ≥3-5X maintained across all indications tested
- Supports favourable risk-benefit profile

STAT-6 Programme — A Second Pipeline Opportunity

STAT-6 is the master transcription factor behind IL-4/IL-13 signalling — the same pathway Dupixent targets upstream to generate over £10 billion in 2024 revenue. CO-002 uses siRNA to silence STAT-6 at the mRNA level, a mechanistically distinct and potentially more complete approach than the degraders and inhibitors currently in clinical development.

Current Landscape

Multiple STAT-6 degraders have entered the clinic with early efficacy signals, confirming target validity. CO-001 is differentiated: siRNA silencing operates upstream of protein production, avoiding the limitations of degradation-dependent or binding-dependent strategies.

Broader Silencing

mRNA-level silencing prevents all STAT-6 isoforms from forming including splice variants that degraders and inhibitors may leave active. This completeness of suppression is the core mechanistic advantage.

Reduced Risk

Partial target engagement (characteristic of degraders and inhibitors) can trigger compensatory isoform upregulation. Silencing at the mRNA level removes this escape mechanism, reducing the risk of resistance or attenuated response over time.

Ind Assessment Underway

The new leadership team is conducting a formal assessment of the CO-001 programme for IND submission readiness and Phase 1 trial design. A go/no-go decision is expected within six to twelve months.